in circulating CD4 + CRTh2 + between EB and HV, or between EB and EA. The Th2 cells in airway (induced sputum) in EB subjects, EA subjects were both significantly higher than that in HV. In the absolute number of Th2 cells: [EB 1651(6033) No significant difference in sputum Th2 cell level was found between EB and EA (P>0.05).
is a rare pulmonary disease that mainly affects the lungs, kidneys, and retroperitoneum, with typical manifestations include dyspnea, pneumothorax, diffuse cystic changes in the lungs, which severely affect lung function, especially diffuse function.
Methods:
We retrospectively collect data of lung function tests of LAM patients consulted in Guangzhou Institute of Respiratory Disease from 2014 to 2018, and analyzed the characteristics of pulmonary function.
Results: A total of 69 LAM patients were included, and the data were analyzed. The patients were females with mean age 37.6 AE 9.4 years old.
For the results of spirometry, 9 cases (13%) were normal, 5 (7%) According to results of spirometry, LAM patients were divided into normal group (n = 9), restrictive group (n = 5), light-moderate obstructive group (n = 33), and severe-very severe obstructive group (n = 22) Data on characteristics and management of IPF patients are still scarce in Taiwan. An IPF non-intervention study would help to gain a better understanding of the epidemiology of the disease and how it is currently managed.
The objective of this non-interventional study is to characterize the IPF population in Taiwan with regard to their demographic, clinical characteristics and treatment.
Methods: IPF patients will be enrolled in a consecutive manner and data will be collected in accordance with real-world clinical practice (baseline, and planned at 1st month and every 3 months afterward, and visits will be in accordance with clinical needs judged by physicians). The enrolment period for the study will be one year and each patient will be followed-up for 2 years. Methods: Subjects were 12 patients (6 men, 6 women, mean age 74.5 years) with both RA and ILD. Types of ILD were idiopathic pulmonary fibrosis pattern 11 and nonspecific interstitial pneumonia pattern 1. The effect of tocilizumab was evaluated before, 1 month after, and 6 months after administration.
Results: Mean levels of matrix metalloproteinase-3 (MMP-3), which is a biomarker of RA disease activity, were 296 AE 319, 200 AE 266, and 202 AE 270 ng/mL, respectively. Significant differences were observed between before and after administration of tocilizumab (before vs 1 month: P < 0.05, before vs 6 months: P < 0.05). Mean levels of Krebs von den Lungen-6 (KL-6) were 718 AE 323, 720 AE 210, and 594 AE 276 U/mL, respectively. No significant differences were observed between before and after administration. Mean levels of lactate dehydrogenase (LDH) were 236 AE 37, 241 AE 44, and 248 AE 51 U/mL, respectively. No significant differences were observed between before and after administration. Chest computed tomography (CT) revealed no differences between before and 1 year after administration.
Conclusion:
The disease activity of RA was significantly improved by administration of tocilizumab, and ILD did not progress. In patients with both RA and ILD, tocilizumab could be administrated safely without progression of ILD. We have analyzed other markers and will present our final results at the APSR 2018 Congress. Methods: We selected 140 spirometry belonging to obstructive lung disease (OLD) patients (including COPD and asthma) and 134 spirometry belonging to DPLD patients from the archive of different research protocols. These patients were diagnosed according to the standard evaluation of diagnosis of the disease. We compared the predicted percentage value of FEF values between the two groups and tried to analyze the capacity of FEF 25-75 to differentiate OLD from DPLD.
